Featured

Non-invasive liquid biopsy to assess myeloma precursor disease pathology



Published
Better early detection methods for precursor disease and targeted interventions to prevent early disease from progressing are needed in the myeloma space. Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study that tested the utility of circulating multiple myeloma cells from non-invasive blood biopsy to accompany bone marrow as a method to monitor disease development. The study illustrated the clinical potential of using liquid biopsies for monitoring and managing precursor disease in the myeloma setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Category
Health
Be the first to comment